{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:07:56Z","timestamp":1772748476838,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>ANA are the most extensively used test for the diagnosis of systemic autoimmune diseases. However, testing by indirect immunofluorescence assays (IIFAs) on HEp-2 cells, the gold standard test, is time-consuming and needs expertise. Thus there is a trend to replace it with other automated solid-phase assays directed against specific ANA. Nonetheless, the Hep-2 cell is an autoantigen array and ANA have been classified into 29 types, some of them with no clear association with a specificity to be detected. It is especially in these uncommon patterns where no clinical relationship is found and no antigenic specificity is detected. Here we retrospectively collected clinical data from patients with confirmed uncommon HEp-2 IIFA patterns to search for an associated clinical condition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted an observational retrospective study including 608 patients with organ-specific and non-organ-specific autoimmune diseases (OSADs and NOSADs, respectively) with a confirmed rare pattern of ANA detected by IIFA on HEp-2 cells in the routine practice of the Spanish European Autoantibodies Standardization Initiative laboratories. Inclusion criteria are the existence of a minimum follow-up of 2\u2009years and the availability of clinical data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nuclear patterns were more frequent in SLE (P\u2009=\u20090.001) and SS (P\u2009=\u20090.001), whereas the cytoplasmic ones were significantly higher in SSc (P\u2009=\u20090.022) and inflammatory myositis (P\u2009=\u20090.016). Mitotic patterns did not show any preferences for a specific disease and 62.7% of them corresponded to the nuclear mitotic apparatus pattern (AC-26). The most frequent NOSADs in patients with the AC-26 pattern were SLE (28.6%), SS (11.9%) and RA (11.9%). The cytoplasmic HEp-2 IIFA patterns were equally distributed in both groups of patients. In the OSAD patients there was no predominant pattern, except for AC-6 in primary biliary cholangitis due to Sp-100 antibodies (P\u2009&amp;lt;\u20090.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Detection of infrequent ANA might be a unique finding with no disease-associated specificities and could lead to the suspicion of an autoimmune disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa831","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T20:34:33Z","timestamp":1605904473000},"page":"3904-3912","source":"Crossref","is-referenced-by-count":14,"title":["Rare immunofluorescence patterns of autoantibodies on HEp-2 cells defined by ICAP identify different autoimmune diseases in the absence of associated specificities: a Spanish multicentre study\u00a0"],"prefix":"10.1093","volume":"60","author":[{"given":"Juan","family":"Irure-Ventura","sequence":"first","affiliation":[{"name":"Servicio Inmunolog\u00eda, Hospital Universitario Marqu\u00e9s de Valdecilla-IDIVAL, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Servicio Inmunolog\u00eda, Hospital Universitario Puerta del Mar, C\u00e1diz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Vergara-Prieto","sequence":"additional","affiliation":[{"name":"Laboratorio de Inmunolog\u00eda y Gen\u00e9tica Molecular, Hospital San Pedro Alc\u00e1ntara, C\u00e1ceres,, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Luisa","family":"Vargas","sequence":"additional","affiliation":[{"name":"Servicio Inmunolog\u00eda y Gen\u00e9tica, Hospital Universitario de Badajoz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana","family":"Quirant","sequence":"additional","affiliation":[{"name":"Servicio Inmunolog\u00eda, Hospital Universitario Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Jurado","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Inmunolog\u00eda, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fern\u00e1ndez-Pereira","sequence":"additional","affiliation":[{"name":"Laboratorio de Inmunolog\u00eda y Gen\u00e9tica Molecular, Hospital San Pedro Alc\u00e1ntara, C\u00e1ceres,, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Mart\u00ednez-C\u00e1ceres","sequence":"additional","affiliation":[{"name":"Servicio Inmunolog\u00eda, Hospital Universitario Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"San Jos\u00e9","sequence":"additional","affiliation":[{"name":"Servicio Inmunolog\u00eda, Hospital Universitario Puerta del Mar, C\u00e1diz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"L\u00f3pez-Hoyos","sequence":"additional","affiliation":[{"name":"Servicio Inmunolog\u00eda, Hospital Universitario Marqu\u00e9s de Valdecilla-IDIVAL, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the GEAI and EASI groups","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"2021080220104693700_keaa831-B1","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1016\/S2665-9913(20)30084-9","article-title":"Utility of repeated antinuclear antibody tests: a retrospective database study","volume":"2","author":"Yeo","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2021080220104693700_keaa831-B2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/ard.2009.127100","article-title":"ANA screening: an old test with new recommendations","volume":"69","author":"Meroni","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021080220104693700_keaa831-B3","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP)","volume":"6","author":"Chan","year":"2015","journal-title":"Front Immunol"},{"key":"2021080220104693700_keaa831-B4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021080220104693700_keaa831-B5","first-page":"879","volume-title":"Ann Rheum Dis","author":"Damoiseaux","year":"2019"},{"key":"2021080220104693700_keaa831-B6","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1515\/cclm-2019-0454","article-title":"Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience","volume":"57","author":"Infantino","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"2021080220104693700_keaa831-B7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-230X-13-50","article-title":"Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection","volume":"13","author":"Stinton","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"2021080220104693700_keaa831-B8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/art.30084","article-title":"Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases","volume":"63","author":"Mariz","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021080220104693700_keaa831-B9","first-page":"533","volume-title":"Autoimmun Rev","author":"Claessens","year":"2018"},{"key":"2021080220104693700_keaa831-B10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021080220104693700_keaa831-B11","first-page":"548","volume-title":"Autoimmun Rev","author":"P\u00e9rez","year":"2018"},{"key":"2021080220104693700_keaa831-B12","first-page":"541","volume-title":"Autoimmun Rev","author":"Bizzaro","year":"2018"},{"key":"2021080220104693700_keaa831-B13","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1515\/cclm-2017-0241","article-title":"Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies","volume":"56","author":"P\u00e9rez","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"2021080220104693700_keaa831-B14","first-page":"293","volume-title":"Autoimmun Rev","author":"Damoiseaux","year":"2019"},{"key":"2021080220104693700_keaa831-B15","first-page":"1","volume-title":"Clin Diagn Lab Immunol","author":"Tri","year":"2002"},{"key":"2021080220104693700_keaa831-B16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaut.2006.09.001","article-title":"Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus","volume":"27","author":"Wandstrat","year":"2006","journal-title":"J Autoimmun"},{"key":"2021080220104693700_keaa831-B17","doi-asserted-by":"crossref","first-page":"698","DOI":"10.12688\/f1000research.14834.1","article-title":"What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study","volume":"7","author":"Jobanputra","year":"2018","journal-title":"F1000Res"},{"key":"2021080220104693700_keaa831-B18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel435","article-title":"Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies","volume":"46","author":"Sato","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2021080220104693700_keaa831-B19","first-page":"4736476","article-title":"PL-7 antisynthetase syndrome in association with Sj\u00f6gren\u2019s, systemic lupus erythematosus, and rheumatoid arthritis","volume":"2020","author":"Jawaid","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"2021080220104693700_keaa831-B20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clim.2003.10.005","article-title":"Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies","volume":"110","author":"Stinton","year":"2004","journal-title":"Clin Immunol"},{"key":"2021080220104693700_keaa831-B21","first-page":"234","volume-title":"Ann Rheum Dis","author":"Vermeersch","year":"2011"},{"key":"2021080220104693700_keaa831-B22","first-page":"1791","volume-title":"Ann Rheum Dis","author":"Vermeersch","year":"2009"},{"key":"2021080220104693700_keaa831-B23","doi-asserted-by":"crossref","first-page":"e11727","DOI":"10.1097\/MD.0000000000011727","article-title":"Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations","volume":"97","author":"Betancur","year":"2018","journal-title":"Medicine (Baltimore"},{"key":"2021080220104693700_keaa831-B24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/ajg.2015.333","article-title":"Antibodies to mitotic apparatus: new association with cholestatic liver disease","volume":"110","author":"Pascual","year":"2015","journal-title":"Am J Gastroenterol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3904\/39543686\/keaa831.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3904\/39543686\/keaa831.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T20:30:46Z","timestamp":1627936246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3904\/6091182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,1,13]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa831","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,1,13]]}}}